This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dorn, G. W. Articles by Matkovich, S. J. Search for Related Content PubMed PubMed Citation Articles by Dorn, G. W., II Articles by Matkovich, S. J. Pubmed/NCBI databases Medline Plus Health Information Heart Diseases Related Collections Clinical genetics Other heart failure Congestive Genetics of cardiovascular disease

(Circulation. 2008;118:216-218.)
© 2008 American Heart Association, Inc.

Editorial

Put Your Chips on Transcriptomics

Gerald W. Dorn, II, MD; Scot J. Matkovich, PhD

From the Center for Pharmacogenomics, Washington University, St Louis, Mo.

Correspondence to Gerald W. Dorn II, MD, Washington University in St Louis, Center for Pharmacogenomics, 660 S Euclid Ave, Campus Box 8086, St. Louis, MO 63110. E-mail gdorn@dom.wustl.edu

Key Words: Editorials • biopsy • genetics • heart-assist device • heart failure

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
The course of any disease is determined by a complex interplay between innate characteristics and environmental triggers. Accordingly, evidence-based risk factor assessment in heart disease requires a detailed family history to gauge inherited features and accurate estimates of smoking, diet, exercise, and other aspects that constitute important extrinsic disease modifiers. The value of traditional risk assessments for individual prognostication is limited, however, by lack of a precise family history to reveal specific genetic makeup on one hand and by interindividual variation in response to environmental events on the other. In diseases such as familial hypertrophic or dilated cardiomyopathies, in which the innate component is far more important than external factors in determining disease onset and progression, genetic testing is increasingly being used to assess individual risks for developing disease and to personalize therapy.¹ However, although there have been some intriguing potential applications,^2,3 the clinical utility of genetic profiling is less clear in nonischemic or idiopathic heart failure syndromes that are polygenic in origin or for which there is greater contribution of environmental factors. Thus, there is a need for clinical tests that not only will reveal a patient’s static genetic makeup but also will define the dynamic changes in gene transcript and protein expression that are a consequence of gene-environment interactions.

Article p 238

The studies of Heidecker et al⁴ in this issue of Circulation help reveal the promise of transcriptional profiling to predict long-term heart failure outcome. Endomyocardial biopsies were obtained early in the course of heart failure from . . . [Full Text of this Article]

This article has been cited by other articles:

				S. J. Matkovich, D. J. Van Booven, K. A. Youker, G. Torre-Amione, A. Diwan, W. H. Eschenbacher, L. E. Dorn, M. A. Watson, K. B. Margulies, and G. W. Dorn II Reciprocal Regulation of Myocardial microRNAs and Messenger RNA in Human Cardiomyopathy and Reversal of the microRNA Signature by Biomechanical Support Circulation, March 10, 2009; 119(9): 1263 - 1271. [Abstract] [Full Text] [PDF]